GlassScriptPhysician profile
Stephen Michael Kelly
NPI 1245367663
$15,279.71
in general payments reported to CMS, 2019-2025
36 companies · $3,292 in 2025
The $3,292 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,994 · 2020: $1,359 · 2021: $967 · 2022: $2,238 · 2023: $2,112 · 2024: $3,318 · 2025: $3,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,627 · Education: $95.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,627.10 |
| Education | $95.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,979.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,248.91 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,769.60 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $675.39 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $614.85 | 2019-2024 | Trulance |
| Janssen Scientific Affairs, LLC | $463.12 | 2019-2022 | |
| Qol Medical, LLC | $429.46 | 2022-2025 | Sucraid, Sucraid |
| Pfizer INC. | $412.13 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $402.22 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $379.09 | 2025 | Rezdiffra |
| Ardelyx, INC. | $354.75 | 2022-2025 | Ibsrela |
| Romark Laboratories, Lc | $298.65 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $264.91 | 2023-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $250.60 | 2022-2024 | Zeposia, Cobenfy |
| Ferring Pharmaceuticals INC. | $250.13 | 2019-2023 | Rebyota |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $200.32 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $176.01 | 2019-2024 | Dificid, Zinplava |
| Lilly USA, LLC | $165.28 | 2025 | Omvoh, Zepbound, Mounjaro |
| Ipsen Biopharmaceuticals, INC | $130.45 | 2025 | Iqirvo |
| Sandoz INC. | $104.23 | 2023-2025 | Hyrimoz |
| Gilead Sciences, INC. | $94.51 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $79.29 | 2022-2023 | Dupixent |
| Novo Nordisk INC | $73.30 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $72.33 | 2019 | |
| Boston Scientific Corporation | $58.72 | 2024 | Alliance II |
| Ironwood Pharmaceuticals, INC | $57.91 | 2019-2024 | |
| Shire North American Group INC | $51.44 | 2019 | |
| Alfasigma USA, INC. | $34.27 | 2020 | |
| Nestle Healthcare Nutrition INC. | $33.31 | 2023 | |
| Allergan, INC. | $30.14 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.95 | 2023 | Cyltezo |
| Capsovision, INC. | $21.89 | 2024 | Capsocam Plus |
| Daiichi Sankyo INC. | $20.98 | 2019 | |
| Vivus LLC | $20.91 | 2025 | Pancreaze |
| Micro-Tech Endoscopy USA, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.